Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML.

NCT04904237 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Refractory Acute Myeloid Leukemia

Interventions

DRUG: Aza-Ven-allo-HSCT

Sponsor

Shanghai Jiao Tong University School of Medicine